NHS Dudley Health Economy Medicines Formulary
Home > 8 Malignant disease and immunosuppression > 8.2 Drugs affecting the immune response > 8.2.4 Other immunomodulating drugs > Multiple sclerosis - natalizumab - NICE TAG TA127

Multiple sclerosis - natalizumab - NICE TAG TA127

1.1 Natalizumab is recommended as an option for the treatment only of rapidly evolving severe relapsing–remitting multiple sclerosis (RES). RES is defined by two or more disabling relapses in 1 year, and one or more gadolinium-enhancing lesions on brain magnetic resonance imaging (MRI) or a significant increase in T2 lesion load compared with a previous MRI.

1.2 People currently receiving natalizumab, but for whom treatment would not have been recommended according to section 1.1 of this guidance, should have the option to continue therapy until they and their clinicians consider it appropriate to stop.

http://www.nice.org.uk/guidance/TA127

Site by Devopa
© Copyright 2019 NHS. All rights reserved.